Zoledronic acid 4 mg infusion every 3 weeks in men with bone metastases in hormone resistant prostate cancer and normal kidney function have 11% fewer skeletal complications including fewer fractures, a longer time to any skeletal problem and less pain
Skeletal problems are common (80%) in patients with advanced prostate cancer from either bone metastases, pathologic fracture, spinal cord compression, or osteopenia from years of hormonal therapy. This randomized study of 643 men who had bone metastases from hormone refractory prostate cancer, performance status 0-2 ECOG, not on chemotherapy, creatinine
- 11% fewer skeletal events such as fracture, spinal cord compression, bone surgery, radiotherapy to bone (33% zoledronic acid v 44% placebo)
- lower fracture rate 13% v 22%
- longer time to a skeletal event, >420 days v 321 days placebo
- better analgesic and quality of life scores.